Patient preference after repeat treatments
with QUTENZA

Not an actual patient.

Angle Shape

Evaluating the preference and willingness for reapplication treatments for painful DPN of the feet1

Safety Study

Methodology

Phase 3, 52-week, multinational, open-label, randomized, controlled safety study of QUTENZA, conducted in Europe.

Patients were randomized to receive 30-minute treatments of QUTENZA + SOC, or SOC alone, to assess the safety of repeat treatment with QUTENZA in patients with painful DPN of the feet.

Patients in the QUTENZA study arms could receive repeated treatments, at the investigator’s discretion, no more frequently than every eight weeks, up to a total of seven treatments over the 52 weeks of the study.

In the US, treatment with QUTENZA may be repeated every three months or as warranted by the return of pain (not more frequently than every three months).

SOC/rescue medications – antidepressants, antiepileptics and/or opioids – were optimized for each patient in each study arm, at the investigator’s discretion.

Rescue medications were for pain associated with topical system treatments and used on days 1 to 5 after topical system treatment only.

SOC was used in painful DPN of the feet at the discretion of the investigator and optimized for patients on an individual basis.

Participants in the study received up to a total of seven QUTENZA treatments over the 52 weeks. At the end of the study, they were asked two questions:

Preference

Looking back over the last 52 weeks, how do you compare the treatment you received with QUTENZA in this study to previous medication or therapies for your pain?

Willingness

Looking ahead, would you undergo this treatment again?

At the end of 52 weeks of trial participation, many patients expressed a preference for, and a willingness to continue with, QUTENZA in their treatment plan.